Jalal A Aram

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Genetic Diversity

Helicobacter Pylori

Chronic Kidney Disease

Top Venues

Antimicrobial agents and chemotherapy

Scientific reports

Hematology (Amsterdam, Netherlands)

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David R Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. Antimicrobial agents and chemotherapy 68 (5) (2024)
Kamal A Hamed, Marc Engelhardt, Laura Lynn Kovanda, Jin Ju Huang, Jean Yan, Jalal A Aram
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 13 (1) (2023)
Kamal A Hamed, Marc Engelhardt, Laura Lynn Kovanda, Jin Ju Huang, Jean Yan, Jalal A Aram
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 13 (1) (2023)
Kamal A Hamed, Marc Engelhardt, Laura Lynn Kovanda, Jin Ju Huang, Jean Yan, Jalal A Aram
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 13 (1) (2023)
Yang Ping, Jing Hongmei, Christian Bellmann, Mónica Inês, Thomas Macmillan, Neil Webb, Jalal A Aram, Olaf Penack
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting. Hematology (Amsterdam, Netherlands) 27 (1) (2022)
Jing Zhang, Yingyuan Zhang, Depei Wu, Guoying Cao, Kamal A Hamed, Amit Desai, Jalal A Aram, Xuan Guo, Rana Fayyad, Oliver Andreas Cornely
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis. Mycoses 64 (4) (2021)